• Study of venetoclax, treosulfan and fludarabine before stem cell transplant in patients with acute myeloid leukemia and myelodysplastic syndrome

    Recruiting

    2 1 1 1
    Germany
  • Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Denmark Germany Hungary Italy The Netherlands +1
  • Study of IMMUNOSTEM gene therapy using modified stem cells for newly diagnosed patients with type 1 diabetes who still produce insulin

    Recruiting

    2 1 1
    Investigated Drugs:
    Italy
  • Study of Cerebrolysin to improve arm function in patients recovering from ischemic stroke

    Recruiting

    3 1 1
    Investigated Diseases:
    Romania
  • Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Germany The Netherlands Spain
  • Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

    Recruiting

    3 1 1
    Investigated Drugs:
    Austria Denmark France Germany Hungary Italy +4
  • Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Spain
  • Study of MTX-463 compared to placebo to assess its safety and effectiveness in adults with idiopathic pulmonary fibrosis

    Recruiting

    2 1 1
    Investigated Diseases:
    Belgium Croatia France Ireland The Netherlands Spain
  • Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

    Recruiting

    2 1 1
    Investigated Drugs:
    Denmark

powered by